Showing results (391-400 of 405) with videos related to
Sort By:
Pageof 41
Nature Communications|July 2, 2025
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trialNan Niu, Jinqi Xue, Guanglei Chen, et al.Nature Communications|November 17, 2022
A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancerNan Niu, Fang Qiu, Qianshi Xu, et al.Cancer Communications (London, England)|September 27, 2018
Development and validation of an endoscopic images-based deep learning model for detection with nasopharyngeal malignanciesChaofeng Li, Bingzhong Jing, Liangru Ke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2022
Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority TrialXiao-Yun Li, Dong-Hua Luo, Ling Guo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Prospective study of tailoring whole-body dual-modality [18F]fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial stagingLin-Quan Tang, Qiu-Yan Chen, Wei Fan, et al.European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trialSu-Mei Cao, Qi Yang, Ling Guo, et al.Nature Communications|March 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trialLi-Ting Liu, Xue-Song Sun, Ting-Ting Quan, et al.NEJM Evidence|April 22, 2025
Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal CarcinomaPei-Yu Huang, Xu-Yin Chen, Xi Ding, et al.The Lancet. Oncology|June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialLi-Ting Liu, Huai Liu, Ying Huang, et al.JAMA Oncology|March 24, 2022
Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical TrialWang-Zhong Li, Xing Lv, Dan Hu, et al.Pageof 41